OncoMatch/Clinical Trials/NCT06208462
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Is NCT06208462 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Lenvatinib for intrahepatic cholangiocarcinoma.
Treatment: Adebrelimab · Lenvatinib · Gemcitabine · Oxaliplatin — Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Cholangiocarcinoma
Disease stage
Required: Stage IB, II, III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic therapy
Exception: biliary drainage allowed
Prior systemic therapy and tumor-related surgical treatment (biliary drainage allowed)
Cannot have received: PD-1 antibody
have received PD1 antibody
Cannot have received: PD-L1 antibody
have received PDL1 antibody
Cannot have received: CTLA-4 antibody
have received CTLA4 antibody
Cannot have received: VEGFR inhibitor (lenvatinib)
have received Lenvatinib
Cannot have received: chemotherapy
have received ... chemotherapy in the past
Lab requirements
Blood counts
Neutrophils ≥1.5*10^9/L; Platelet ≥80*10^9/L; Hemoglobin ≥9g/dl; Serum albumin ≥3g/dl
Kidney function
Serum creatinine ≤ 1.5 times the upper limit of normal value, creatinine clearance ≥60 ml/min
Liver function
Bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST ≤ 2 times the upper limit of normal value
The functional indicators of vital organs meet the following requirements ... Neutrophils ≥1.5*10^9/L; Platelet ≥80*10^9/L; Hemoglobin ≥9g/dl; Serum albumin ≥3g/dl; ... Bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST≤ 2 times the upper limit of normal value; ... Serum creatinine ≤ 1.5 times the upper limit of normal value, creatinine clearance ≥60 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06208462 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IB or II or III or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages